At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PCVX Vaxcyte, Inc.
Pre-Mkt 02-06 04:45:12 EST
53.91
-1.37
-2.48%
High56.58Low53.12Vol1.86M
Open55.21D1 Closing55.28Amplitude6.26%
Mkt Cap7.76BTradable Cap6.31BTotal Shares144.00M
T/O101.58MT/O Rate1.59%Tradable Shares116.97M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
GlobeNewswire  ·  05:05
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
Vaxcyte Closes Public Offering of Shares
MT Newswires Live  ·  02-03
Vaxcyte Closes Public Offering of Shares
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
GlobeNewswire  ·  02-03
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Vaxcyte Price Target Maintained With a $116.00/Share by Guggenheim
Dow Jones  ·  02-02
Vaxcyte Price Target Maintained With a $116.00/Share by Guggenheim
Vaxcyte (PCVX) Valuation Check After $550 Million Follow On Equity Offering
Simply Wall St.  ·  02-02
Vaxcyte (PCVX) Valuation Check After $550 Million Follow On Equity Offering
BUZZ-U.S. STOCKS ON THE MOVE-ResMed, Stryker, ALX Oncology
Reuters  ·  01-30
BUZZ-U.S. STOCKS ON THE MOVE-ResMed, Stryker, ALX Oncology
BUZZ-Vaxcyte edges higher after upsized $550 mln equity raise
Reuters  ·  01-30
BUZZ-Vaxcyte edges higher after upsized $550 mln equity raise
Vaxcyte Inc - Selling 11,000,000 Shares at $50 per Share
THOMSON REUTERS  ·  01-30
Vaxcyte Inc - Selling 11,000,000 Shares at $50 per Share
Vaxcyte Announces Pricing of $550 Million Public Offering
THOMSON REUTERS  ·  01-30
Vaxcyte Announces Pricing of $550 Million Public Offering
Vaxcyte secondary being re-offered at $50 per share
TIPRANKS  ·  01-30
Vaxcyte secondary being re-offered at $50 per share
Vaxcyte offering marketed at $50 per share, Bloomberg says
TIPRANKS  ·  01-30
Vaxcyte offering marketed at $50 per share, Bloomberg says
Vaxcyte Launches $500 Million Public Offering
MT Newswires Live  ·  01-30
Vaxcyte Launches $500 Million Public Offering
Vaxcyte Inc - Commences $500 Mln Public Offering
THOMSON REUTERS  ·  01-30
Vaxcyte Inc - Commences $500 Mln Public Offering
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire  ·  01-30
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
Why Vaxcyte (PCVX) Is Up 13.2% After Advancing Adult Phase 3 And Infant VAX-31 Trials
Simply Wall St.  ·  01-26
Why Vaxcyte (PCVX) Is Up 13.2% After Advancing Adult Phase 3 And Infant VAX-31 Trials
Analysts Are Bullish on These Healthcare Stocks: Vaxcyte (PCVX), Guardant Health (GH)
TIPRANKS  ·  01-24
Analysts Are Bullish on These Healthcare Stocks: Vaxcyte (PCVX), Guardant Health (GH)
Why Your Pneumonia Shot Is About To Get A Massive Upgrade
Benzinga_recent_news  ·  01-23
Why Your Pneumonia Shot Is About To Get A Massive Upgrade
Vaxcyte provides update on development of VAX-31 pneumococcal vaccine
TIPRANKS  ·  01-23
Vaxcyte provides update on development of VAX-31 pneumococcal vaccine
Vaxcyte: Vax-31 Adult Phase 3 Noninferiority Trial (Opus-1) Continues to Enroll Subjects, With Topline Data Expected in Fourth Quarter of 2026
THOMSON REUTERS  ·  01-23
Vaxcyte: Vax-31 Adult Phase 3 Noninferiority Trial (Opus-1) Continues to Enroll Subjects, With Topline Data Expected in Fourth Quarter of 2026
Vaxcyte: Expects to Report Topline Safety, Tolerability and Immunogenicity Data From Both Opus-2 and Opus-3 Phase 3 Studies in First Half of 2027
THOMSON REUTERS  ·  01-23
Vaxcyte: Expects to Report Topline Safety, Tolerability and Immunogenicity Data From Both Opus-2 and Opus-3 Phase 3 Studies in First Half of 2027

Introduction

Company Name.
Vaxcyte, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against these emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Issue price:
--